MSD pips AZ in first-to-market race

Posted 13 November 2026 AM

MSD is winning the race to bring the first oral PCSK9 inhibitor to market, after its daily pill enlicitide decanoate produced similar results to existing injectables in two Phase 3 trials.

Both MSD and AstraZeneca are developing PCSK9 inhibitor once-daily pills. Sales of the three approved injectable PCSK9 inhibitors - Amgen’s Repatha, Sanofi’s Praluent and Novartis’s Leqvio - are growing but have failed to meet expectations.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here